The latest research results in China can provide a direct basis for precision medicine for stomach cancer

diffuse stomach cancer is a disease or several diseases? How long is the patient expected to survive? Is chemotherapy effective after surgery? The latest results of Chinese scientists show that diffuse stomach cancer can be divided into three subtypes at the proteomic level, with different subtype patients with different total survival times and sensitivity to chemotherapy.
, March 8, Beijing time, the internationally renowned academic journal
published the latest results of the diffuse gastric cancer proteomics study conducted by the Military Medical Research Institute of the PLA Academy of Military Sciences and Peking University Cancer Hospital.
Qin Qi, director and researcher of the National Protein Science Center (Beijing) of the Military Medical Research Institute, said that this proteomics does not rely on any genomic information, reflecting the importance and comprehensiveness of the information provided by proteins as direct implementers of function in clinical science, and can provide a direct basis for precision medicine for stomach cancer.
gastric cancer can be morphologically divided into intestinal, diffuse and mixed type, in which diffuse gastric cancer is called "gastric cancer in stomach cancer", there is no effective targeted therapy. According to the data, there are about 680,000 new cases of stomach cancer in China each year, accounting for about half of all cases worldwide.The familiar genetic sequencing can only provide very limited clues for the precision medicine of tumors, qin said, and this confusion can now be solved at the protein level,
"in the future, clinically, proteomic analysis of tumors, you can know what kind of tumor this is, what kind of treatment should be taken, what kind of treatment should not be taken." The
team also screened 23 target gastric cancer candidate protein drugs that were closely related to the patient's estimated survival time. "This suggests that effective targeted drugs for stomach cancer are most likely to be developed for these targets, " says Mr Qin. Since
2012, Qin's team has embarked on the journey to map the first diffuse gastric cancer proteomics and tumor-driven gene variants. In June 2016, the team completed mass spectrometry of 84 samples of gastric and cancerous tissue, identifying 11,340 different gene products that covered tumor cells and all possible expressions of proteins in the tumor micro-environment, thus painting the entire proteomic spectrum of diffuse gastric cancer for the first time. (Source: Xinhua News Agency, Wang Dongming, Song Dong, Zhuang Yingna